Analysis the alpha-protein level in hepatitis patient as an aid in accessing the degree in which it generates to hcc

Project Abstract

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and is known to be one of the leading causes of cancer-related deaths worldwide. Chronic hepatitis B and C infections are major risk factors for the development of HCC. Alpha-fetoprotein (AFP) is a commonly used biomarker for HCC surveillance and diagnosis. However, the use of AFP alone has limitations in terms of sensitivity and specificity. This study aimed to analyze the role of alpha-fetoprotein (AFP) levels in hepatitis patients as an aid in assessing the risk of progression to hepatocellular carcinoma (HCC). A total of 200 patients with chronic hepatitis B and C infections were included in the study. The patients were divided into two groups Group A with elevated AFP levels and Group B with normal AFP levels. The results showed that patients in Group A with elevated AFP levels had a significantly higher risk of developing HCC compared to those in Group B with normal AFP levels. Additionally, the degree of AFP elevation was correlated with the stage and prognosis of HCC in hepatitis patients. Patients with AFP levels above a certain threshold had a poorer prognosis and lower survival rates. Furthermore, the study found that monitoring AFP levels in hepatitis patients over time could help in the early detection of HCC and improve patient outcomes. Regular monitoring of AFP levels, along with other imaging and diagnostic tests, could aid in the timely intervention and management of HCC in high-risk patients. In conclusion, the analysis of alpha-fetoprotein levels in hepatitis patients can serve as a valuable tool in assessing the risk of progression to hepatocellular carcinoma. Elevated AFP levels are associated with an increased risk of HCC development, and monitoring AFP levels can aid in the early detection and management of HCC in high-risk individuals. Further research is needed to establish standardized protocols for AFP monitoring and to explore other biomarkers that may complement AFP in the surveillance and diagnosis of HCC.

Project Overview

<p> </p><p><strong>1.0 &nbsp; &nbsp; &nbsp; INTRODUCTION</strong></p><p>Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It accounts for 60% of all cancer world wide (Melissa 2004). The most significance cause is the presence of cirrhosis. HCC has unique geographic sex, age distribution that are likely determined by specific actiology factor. It’s distribution also varies among ethnic group within the same country (Munoz 1989). A high incidence of hepatitis B and C may have been an important factor contributing to the development of liver disease (HCC and Cirrhosis) in south eastern Nigeria. However, a recent trend which reveals an increase in cases of liver cirrhosis and hepatitis in our environment suggest that there could be other contributory factors perculiar to our environment besides hepatitis B and C which could be possible explanation to the recent trend. In so doing, it would be necessary to look into the various predisposing/causative factors of chronic hepatitis which could lead to increased cases of liver cirrhosis and HCC in our environment. The risk of developing HCC differs depending on the cause of cirrhosis. For example, cirrhosis due to hepatitis B has a high risk of leading to HCC while the risk of HCC in people with primary biliary cirrhosis, although present is very low. All these human hepatitis viruses are RNA viruses except for hepatitis B virus, which is a DNA virus. Although these viruses can be distinguished by their molecular and antigenic properties, all types of viral hepatitis produce clinically similar illnesses. These range from asymptomatic and unapparent to fulminant and fatal acute infections common to all types, on one hand, and from subclinical persistent infections to rapidly progressive liver disease with cirrhosis and even hepatocullular carcinoma (HCC), common to the blood-borne types (HBV and HCV). Without specific virological test, it is not possible to determine which hepatitis virus is responsible for a case of hepatitis. (Kathleen park et al., 2004).</p> <br><p></p>